Corona Remedies IPO GMP 335 Today (12 Oct), Price Band, Subscription Status, Allotment Date

Corona Remedies IPO Review & Analysis

Our reading of the numbers below — growth rates, margins, pricing and demand are calculated from the company's own filed figures, not copied from anywhere.

Corona Remedies is a mainboard issue raising ₹655.37 Crores, offered in a band of ₹1008–₹1062 per share. At the upper end that is 106.2 times the ₹10 face value, so ₹1052 of every share subscribed is share premium rather than capital.

A retail application for Corona Remedies needs one lot of 14 shares, which works out to ₹14,868 at the upper band of ₹1062. That is close to the ₹15,000 ceiling SEBI expects for a single retail lot, so an investor applying at cut-off is committing nearly the full retail limit per application. Retail applications are capped at ₹2,00,000, which here is 13 lots; bidding above that moves the application into the non-institutional category, and the large-HNI bucket begins at ₹10,00,000, or about 68 lots.

For Corona Remedies, allotment is finalised on 11 Dec 2025, the shares list on 15 Dec 2025.

The issue is reserved 50% to qualified institutional buyers, 15% to non-institutional investors, 35% to retail. A 35% retail share is the wider end of the range, which improves the odds for small applications when the book is only modestly oversubscribed. An oversubscribed retail portion is not allotted in proportion to the amount applied for: applications are reduced to single lots and drawn by lot, so several small applications from different PANs are more effective than one large one.

The book is 144.49x subscribed across all categories. That headline covers institutional, non-institutional and retail bids together, and allotment odds are decided within each category separately — an issue can be heavily subscribed overall while the retail portion is comfortable, or the other way round. An oversubscribed retail book is settled by a draw on single-lot applications, so more distinct PANs help where a bigger single bid does not.

Bigshare Services Pvt. Ltd is the registrar for this issue, which means the allotment status for Corona Remedies is published on their portal from 11 Dec 2025. A PAN, application number or demat client ID is enough to look it up; the credited shares also appear in the demat account itself a day or so before listing.

A grey market premium of ₹335 on the upper band of ₹1062 implies a listing gain of roughly 31.5%. The grey market is unofficial and unregulated, the premium can change daily, and it has no bearing on allotment — treat it as a sentiment reading, not a forecast.

The figures above are worked out from the issue's own filed numbers and are for information only. They are not investment advice — read the RHP before you apply.